We know that honest feedback is hard to come by, & especially so for women & minorities. Had this Q posed to me: how do I get specific, actionable feedback if no one seems to be offering it? I'd say first, look for the "hidden message". Sometimes a vague piece of advice...1/6
...actually holds something useful. "You often ghost me on projects we do together" can be coded as "Try to increase your visibility within the group." Sometimes you have to ask a few Qs to really get at the real message. 2nd - if you get a piece of feedback that is clear...2/6
...from one person, try bringing it to someone who never offers anything specific. "I have gotten some feedback that I should _____; do you have any advice around that?" Research shows men sometimes worry women will get emotional if they are very frank, so by getting an...3/6
...issue out in the open, you invite discussion and show that you really want input. The convo may then go to other useful pieces of advice. I also suggest following up honest advice with asking whether you can periodically get the person's views on how you're advancing in...4/6
...that area. E.g., if speaking skills are an area for improvement, ask for feedback each time you present something to your team. Not only will you hone in on what's really the issue, you will be bringing the person's attention to how you are progressing (key since...5/6
...changing ppl's views of you can be hard) and you'll also be enlisting them as an advisor. Ppl tend to view those whom they've helped more favorably than those whom they haven't (cognitive dissonance). 6/6

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Sara Nayeem

Sara Nayeem Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @SaraNayeem

10 Dec
Suggestion for biopharma co's perfecting their pitch decks: run your deck by a non-scientist who has a discerning eye. Ask them if the conclusions are clear, particularly on slides that lay out your data. They may not be familiar w/ the experiments or models, but they..1/5
...should be able to generally follow your argument. Conclusions can be communicated in the title, a strap box at the bottom of the page, a summary slide... Somehow. Don't make the mistake of letting data "stand on its own." Why bother with this if biopharma inv's are...2/5
...generally facile w/ scientific data? A few reasons: 1) VCs have limited time & attention span: if it takes too much work to discern the takeaways, someone might take away the wrong thing (or nothing at all; no impression = a bad impression). & don't save your key points...3/5
Read 5 tweets
7 Dec
One area where biopharma co's sometimes fail to bound the downside risk is around regulatory. As the FDA has become more comfortable with surrogate endpoints, more co's (esp in the rare dz space) are assuming paths to accelerated approval. Investors like efficient clinical...1/7
...development plans. But the specter of the FDA "requiring outcome data" pre-approval always looms. My advice is to address this head-on. If there are clear precedents in your dz setting for accelerated approval on a surrogate endpoint, then you have a strong argument. If...2/7
...there are precedents in related dz's, you have some argument. If you just have KOL opinions that a non-clinical endpoint (imaging, diagnostic testing, biomarker, etc.) SHOULD be a good surrogate, then expect some skepticism. Of course regulatory feedback is key but co's...3/7
Read 7 tweets
2 Dec
For biopharma co's advanced enough that you have built a revenue forecast, I'd like to make a case for 1) incorporating conservatism and / or 2) showing a few scenarios (downside, base, upside). Many co's put forth a very aggressive forecast b/c they assume (rightly)...1/7
...that investors will discount their projections somewhat. However, if the forecast far exceeds comps that ppl may reference, assumes a very optimistic penetration rate, or fails to account for things such as physician uptake, insurance coverage rate, or adherence, you run...2/7
...the risk of losing credibility. Inv's may simply disengage at that point. If instead you incorporate realistic assumptions, explain these assumptions, & provide a model that allows key inputs to be tweaked, you'll likely get more engagement. E.g., if you have to say...3/7
Read 7 tweets
20 Nov
Appreciate this article summarizing points I made re: #diversity in biotech & VC from a panel at the BioPharm America Digital Conference. Key ideas: 1) use recruiters & not just word of mouth to access a more diverse group of candidates; 2) anonymize case studies & if...1/7
...possible, even candidate names on the initial resume review (studies show the same resume with a minority name on it will produce fewer interview offers than a white-sounding name, & that ppl tend to judge the same piece of work more harshly if they believe it was...2/7
...written by a minority or a woman than if they believe it was written by a white male); 3) expand network to meet ppl earlier in their careers & shift searches to ppl a bit younger when possible - in an industry in which diverse professionals are underrepresented at the...3/7
Read 7 tweets
1 Nov
When I saw this headline, I feared the article would be reductionist and coy. But the authors hit on many of the right points: 1) individuals’ political beliefs don’t solely (or even mostly) relate to potential impact on the industry in which they... 1/7
statnews.com/2020/10/30/is-…
...work; 2) Trump’s deep-seated antipathy to science is an affront to drug developers; 3) Trump’s politicization of the drug dev’t process & undermining of the FDA & CMC threaten our industry; 4) Trump may not raise the corp tax rate or seek campaign finance reform, but...2/7
...his approach to the drug industry has been hostile, unpredictable, & uninformed by dialogue. The article doesn’t note Trump’s desire to dismantle ObamaCare, which would have a negative impact on many ppl’s health as well as the biopharma industry. It also doesn’t mention...3/7
Read 7 tweets
29 Oct
Thread for folks looking for roles in biopharma VC. Nearly every week I speak to someone who wants to get into biopharma VC. One high-level theme: even for entry roles, you *generally* need to check the box “understands science” as well as the box “can do basic financial... 1/9
...modeling”. Often ppl who reach out to me have substantial scientific creds but don’t have any finance experience. That’s not a deal killer for every firm or role – with a very strong scientific background and some other form of business training (non-finance business...2/9
...roles, MBA or relevant undergrad major, even being self-taught) many people can do just fine in biopharma VC (I wouldn’t try to do healthcare services VC/PE, though, unless you’re a whiz at financial modeling). Others may enter the industry from an entrepreneurial /... 3/9
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!